High-dimensional gene expression profiling studies in high and low responders to primary smallpox vaccination

Journal of Infectious Diseases

Volumn 206, Issue 10, 2012, Pages 1512-1520

  Haralambieva, Iana H ^a,b   Oberg, Ann L ^c   Dhiman, Neelam ^a,b   Ovsyannikova, Inna G ^a,b   Kennedy, Richard B ^a,b   Grill, Diane E ^c   Jacobson, Robert M ^a,b   Poland, Gregory A ^a,b  

^a MAYO CLINIC   (United States)

^b Program in Translational Immunovirology and Biodefense   (United States)

^c Mayo Clinic ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERFERON; SMALLPOX VACCINE; TRANSCRIPTOME;

ADULT; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; CAPRIN1 GENE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHEMOKINE GENE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DAPP1 GENE; DOSE RESPONSE; EGR3 GENE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; HISTONE GENE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; INTERFERON GENE; LAMP3 GENE; LNPEP GENE; MALE; MICROARRAY ANALYSIS; NONHUMAN; NORMAL HUMAN; NR4A2 GENE; NUCLEAR FACTOR GENE; PRIORITY JOURNAL; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TLR8 GENE; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR GENE; VACCINIA VIRUS; XRN1 GENE; ZINC FINGER PROTEIN GENE;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOKINES; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; PROTEIN ARRAY ANALYSIS; RNA, MESSENGER; SMALLPOX; SMALLPOX VACCINE; TRANSCRIPTOME; YOUNG ADULT;

EID: 84867736570     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis546     Document Type: Article

References (50)

1. Nalca A, Rimoin AW, Bavari S, Whitehouse CA. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 2005; 41:1765-71.
2. Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA. The immunology of smallpox vaccines. Curr Opin Immunol 2009; 21:314-20.
3. Lane JM. Immunity to smallpox and vaccinia: the future of smallpox vaccines. Expert Rev Clin Immunol 2006; 2:325-7.
4. Formenty P, Muntasir MO, Damon I, et al. Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan,
5. Emerg Infect Dis 2010; 16:1539-45.
6. Schatzmayr HG, Costa RV, Goncalves MC, D'Andrea PS, Barth OM. Human and animal infections by vaccinia-like viruses in the state of Rio de Janeiro: a novel expanding zoonosis. Vaccine 2011; 29 Suppl 4: D65-9.
7. Reynolds MG, Damon IK. Outbreaks of human monkeypox after cessation of smallpox vaccination. Trends Microbiol 2012; 20:80-7.
8. Moussatche N, Damaso CR, McFadden G. When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond. J Infect Dev Ctries 2008; 2:156-73.
9. Reynolds MG, Davidson WB, Curns AT, et al. Spectrum of infection and risk factors for human monkeypox, United States, 2003. Emerg Infect Dis 2007; 13:1332-9.
10. Hammarlund E, Lewis MW, Hanifin JM, Mori M, Koudelka CW, Slifka MK. Antiviral immunity following smallpox virus infection: a case-control study. J Virol 2010; 84:12754-60.
11. Kennedy R, Ovsyannikova IG, Pankratz VS, et al. Gender effects on humoral immune response to smallpox vaccine. Vaccine 2008; 27:3319-23.
12. Haralambieva IH, Ovsyannikova IG, Dhiman N, et al. Common SNPs/haplotypes in IL18R1 and IL18 genes are associated with variations in humoral immunity to smallpox vaccination in Caucasians and African Americans. J Infect Dis 2011; 204:433-41.
13. Kennedy R, Pankratz VS, Swanson E, Watson D, Golding H, Poland GA. Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay. Clin Vaccine Immunol 2009; 16:1105-12.
14. Umlauf BJ, Ovsyannikova IG, Haralambieva IH, et al. Correlations between vaccinia-specific immune responses within a cohort of armed forces members. Viral Immunol 2011; 24:415-20.
15. Oberg AL, Dhiman N, Grill DE, Ryan JE, Kennedy RB, Poland GA. Optimizing high dimensional gene expression studies for immune response following smallpox vaccination using Taqman(R) Low density immune arrays. J Immunol Methods 2011; 366:69-78.
16. Dudoit S, Yang YH, Callow MJ, Speed TP. Statistical methods for identifying genes with differential expression in replicated cDNA microarray experiments. Statistica Sinica 2002; 12:111-39.
17. Ballman KV, Grill DE, Oberg AL, Therneau TM. Faster cyclic loess: normalizing RNA arrays via linear models. Bioinformatics 2004; 20:2778-86.
18. Chu TM, Weir B, Wolfinger R. A systematic statistical linear modeling approach to oligonucleotide array experiments. Math Biosci 2002; 176:35-51.
19. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary, NC: SAS Institute, 2002.
20. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. New York: Springer, 2004.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B 1995; 57:289-300.
22. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100:9440-5.
23. Stanley SL Jr, Frey SE, Taillon-Miller P, et al. The immunogenetics of smallpox vaccination. J Infect Dis 2007; 196:212-9.
24. Reif DM, McKinney BA, Motsinger AA, et al. Genetic basis for adverse events after smallpox vaccination. J Infect Dis 2008; 198:1-7.
25. McKinney BA, Reif DM, Rock MT, et al. Cytokine expression patterns associated with systemic adverse events following smallpox immunization. J Infect Dis 2006; 194:444-53.
26. Reif DM, Motsinger-Reif AA, McKinney BA, Rock MT, Crowe JE Jr, Moore JH. Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination. Genes Immun 2009; 10:112-9.
27. Davis NA, Crowe JE Jr, Pajewski NM, McKinney BA. Surfing a genetic association interaction network to identify modulators of antibody response to smallpox vaccine. Genes Immun 2010; 11:630-6.
28. Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. Human leukocyte antigen genotypes in the genetic control of adaptive immune responses to smallpox vaccine. J Infect Dis 2011; 203:1546-55.
29. Rubins KH, Hensley LE, Jahrling PB, et al. The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci USA 2004; 101:15190-5.
30. Harenberg A, Guillaume F, Ryan EJ, Burdin N, Spada F. Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells. Vaccine 2008; 26:5004-13.
31. Scherer CA, Magness CL, Steiger KV, et al. Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections. Vaccine 2007; 25:6458-73.
32. Guerra S, Najera JL, Gonzalez JM, et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol 2007; 81:8707-21.
33. Guerra S, Lopez-Fernandez LA, Conde R, Pascual-Montano A, Harshman K, Esteban M. Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol 2004; 78:5820-34.
34. Sheikh MS, Fornace AJ Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000; 14:1509-13.
35. Yang Z, Bruno DP, Martens CA, Porcella SF, Moss B. Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci USA 2010; 107:11513-8.
36. Challa S, Woelfel M, Guildford M, Moquin D, Chan FK. Viral cell death inhibitor MC159 enhances innate immunity against vaccinia virus infection. J Virol 2010; 84:10467-76.
37. Georgopoulos K, Winandy S, Avitahl N. The role of the Ikaros gene in lymphocyte development and homeostasis. Annu Rev Immunol 1997; 15:155-76.
38. Patera AC, Pesnicak L, Bertin J, Cohen JI. Interleukin 17 modulates the immune response to vaccinia virus infection. Virology 2002; 299:56-63.
39. Yao C, Sakata D, Esaki Y, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009; 15:633-40.
40. Peng G, Guo Z, Kiniwa Y, et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005; 309: 1380-4.
41. Niiro H, Allam A, Stoddart A, Brodsky FM, Marshall AJ, Clark EA. The B lymphocyte adaptor molecule of 32 kilodaltons (Bam32) regulates B cell antigen receptor internalization. J Immunol 2004; 173:5601-9.
42. Zhou Z, Xue Q, Wan Y, Yang Y, Wang J, Hung T. Lysosome-associated membrane glycoprotein 3 is involved in influenza A virus replication in human lung epithelial (A549) cells. Virol J 2011; 8:384.
43. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008; 89(Pt 1):1-47.
44. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8:559-68.
45. Zhu J, Martinez J, Huang X, Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 2007; 109:619-25.
46. Ovsyannikova IG, Haralambieva IH, Dhiman N, et al. Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis 2010; 201:207-13.
47. Ovsyannikova IG, Dhiman N, Haralambieva IH, et al. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum Genet 2010; 127:207-21.
48. Haralambieva IH, Dhiman N, Ovsyannikova IG, et al. 2′-5′- Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine. Hum Immunol 2010; 71:383-91.
49. Haralambieva IH, Ovsyannikova IG, Umlauf BJ, et al. Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine. Vaccine 2011; 29:8988-97.
50. Haralambieva IH, Poland GA. Vaccinomics, predictive vaccinology and the future of vaccine development. Future Microbiol 2010; 5:1757-60.